Wm Kevin Kelly - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Wm Kevin Kelly

Showing results (21-30 of 37) with videos related to

Pageof 4

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022

Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate CancerZachary Quinn, Benjamin Leiby, Guru Sonpavde, et al.

European Journal of Cancer (Oxford, England : 1990)|June 18, 2015

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancerMaha Hussain, Dana Rathkopf, Glenn Liu, et al.

Prostate Cancer and Prostatic Diseases|February 12, 2024

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumabAndrew B Nixon, Yingmiao Liu, Qian Yang, et al.

Biorxiv : the Preprint Server for Biology|March 30, 2023

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancerNicolas Gordon, Peter T Gallagher, Neermala Poudel Neupane, et al.

The Oncologist|May 4, 2026

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysisAbhiraj Saxena, Marc Yorker, Nicholas A Zorko, et al.

Urologic Oncology|May 21, 2014

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United StatesAndrea B Apolo, Joseph W Kim, Bernard H Bochner, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006

Pharmacokinetics and toxicity of weekly docetaxel in older patientsArti Hurria, Mark T Fleming, Sharyn D Baker, et al.

Molecular Oncology|January 14, 2026

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancerNicolas Gordon, Peter T Gallagher, Orly I Richter, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenouslyWm Kevin Kelly, Victoria M Richon, Owen O'Connor, et al.

American Journal of Cancer Therapy and Pharmacology|January 13, 2015

A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSAJianqing Lin, Tingting Zhan, Danielle Duffy, et al.

Pageof 4

Search research articles

Showing results (21-30 of 37) with videos related to

Sort By:

Pageof 4

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022

Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate CancerZachary Quinn, Benjamin Leiby, Guru Sonpavde, et al.

European Journal of Cancer (Oxford, England : 1990)|June 18, 2015

Prostate Cancer and Prostatic Diseases|February 12, 2024

Biorxiv : the Preprint Server for Biology|March 30, 2023

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancerNicolas Gordon, Peter T Gallagher, Neermala Poudel Neupane, et al.

The Oncologist|May 4, 2026

Urologic Oncology|May 21, 2014

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United StatesAndrea B Apolo, Joseph W Kim, Bernard H Bochner, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006

Pharmacokinetics and toxicity of weekly docetaxel in older patientsArti Hurria, Mark T Fleming, Sharyn D Baker, et al.

Molecular Oncology|January 14, 2026

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancerNicolas Gordon, Peter T Gallagher, Orly I Richter, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenouslyWm Kevin Kelly, Victoria M Richon, Owen O'Connor, et al.

American Journal of Cancer Therapy and Pharmacology|January 13, 2015

A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSAJianqing Lin, Tingting Zhan, Danielle Duffy, et al.

Pageof 4